Advertisement

Kombinierte Therapien

  • E. Schneider

Zusammenfassung

Die Therapie des Parkinson-Syndroms stellt — sieht man von einer beginnenden, die Aktivitäten des Kranken nicht wesentlich behindernden Symptomatik ab — frÜher oder später eine Kombinationsbehandlung mit einem oder mehreren Parkinsonmitteln dar. Es hat sich gezeigt, daß alle in den vorangegangenen Kapiteln besprochenen Substanzgruppen miteinander kombiniert werden kÖnnen. Es herrscht des weiteren übereinstimmung darüber, daß die L-Dopa-Substitutionstherapie die Basisbehandlung des Parkinson-Syndroms darstellt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Appleton DB, Eadie MJ, Sutherland JM (1970) Amantadine hydrochloride in the treatment of parkinsonism: a controlled trial. Med J Aust 2: 626–629PubMedGoogle Scholar
  2. Barbeau A, Mars H, Botez MI, Joubert M (1971) Amantadine — HCl (Symmetrel) in the management of Parkinson’s disease. Double-blind crossover study. Can Med Assoc 105: 42–46Google Scholar
  3. Beasly BL, Nutt JG, Davenport RW, Chase TN (1980) Treatment with tryptophan of levodopa-associated psychiatric disturbances. Arch Neurol 37: 155–156CrossRefGoogle Scholar
  4. Benkert O, Hippius H (1996) Psychiatrische Pharmakotherapie. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  5. Berger JR, Weiner WJ (1985) Exacerbation of Parkinson’s disease following the withdrawal of amantadine. Neurology 35[Suppl 1]: 200Google Scholar
  6. Bianchine JR, Sunyapridakul L (1973) Interactions between levodopa and other drugs: significance in the treatment of Parkinson’s disease. Drugs 6: 364–388PubMedCrossRefGoogle Scholar
  7. Birkmayer W, Riederer P (1985) Die Parkinsonkrankheit. Biochemie, Klinik, Therapie, 2. Aufl. Springer, Wien New York, S 36–48Google Scholar
  8. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-Deprenyl to Madopar® treatment in Parkinson’s disease: a long-term study. J Neural Transm 64: 113–127PubMedCrossRefGoogle Scholar
  9. Bonucelli U, D’Antonio P, D’Avino C, Piccini P, Muratorio A (1995) Dihydroergocryptine in the treatment of Parkinson’s disease. J Neural Transm 45 [Suppl]: 239–245Google Scholar
  10. Calne D, Horowski R, Mc Donald RJ, Wuttke W (eds) (1981) Lisuride and other dopamine agonists. Raven Press, New YorkGoogle Scholar
  11. Csanda E, Tarczy M (1983) Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand [Suppl] 95: 117–122CrossRefGoogle Scholar
  12. Csanda E, Tarczy M (1987) Selegiline in the early and late phases of Parkinson’s disease. J Neural Transm [Suppl] 25: 105–113Google Scholar
  13. Dallos V, Heatherfield K, Stone P, Alten FAD (1970) Use of amantadme in Parkinson’s disease. Results of a double blind trial. Br Med J 4: 24–36PubMedCrossRefGoogle Scholar
  14. de Devlttis E, D’Andrea F, Signorelli CD, Cerillo A (1972) L’amantadine nel trattamento dell’ ipokinesia transitoria di pazienti parkinsoniani in corso di terapia con L-Dopa. Minerva Med 409: 4007–4008Google Scholar
  15. Deuschl G (1992) Tremor. In: Hopf HC, Poeck K, Schliack H (Hrsg) Neurologie in Praxis und Klinik. Thieme, Stuttgart New York, S 4.53–4.61Google Scholar
  16. Duvoisin RC, Barret C, Schear M, Hoehn M, Yahr MD (1969) The use of L-Dopa in parkinsonism. In: Gillingham GFJ, Donaldson JML (eds) The Third Symposium on Parkinson’s Disease. Livingstone, Edinburgh, pp 185–192Google Scholar
  17. Factor SA, Weiner WJ (1993) Early combination therapy with bromocriptine and levodopa in Parkinson’s disease. Mov Disord 8: 257–262PubMedCrossRefGoogle Scholar
  18. Fahn S, Isgreen WP (1975) Long term evaluation of amantadine and levodopa combination in parkinsonism by double blind cross-over analyses. Neurology 25: 695–700PubMedCrossRefGoogle Scholar
  19. Fahn S, Marsden C D, Calne D, Goldstein M (eds) (1987) Recent developments in Parkinson’s disease. Macmillan Healthcare Information, New JerseyGoogle Scholar
  20. Fehling C (1973) The effect of adding amantadine to optimum L-Dopa dosage in Parkinson’s syndrome. Acta Neurol Scand 49: 245–251PubMedCrossRefGoogle Scholar
  21. Fischer PA (1988) Aktuelle Parkinsontherapie: Heutiges Konzept für die Anwendung von L-Dopa. Akt Neurol 15: 38–41CrossRefGoogle Scholar
  22. Fischer PA, Baas H (1987) Therapeutic efficacy of R-(-)-deprenyl therapy in advanced parkinsonism. J Neural Transm [Suppl] 25: 137–147Google Scholar
  23. Fischer PA, Frieling B (1989) (Hrsg) Morbus Parkinson — neue MÖglichkeiten mit Lisurid. De Gruyter, Berlin New YorkGoogle Scholar
  24. Fischer PA, Przuntek H, Maier M, Welzel D (1984) Kombinationsbehandlung frÜher Stadien des Parkinson-Syndroms mit Bromocriptin und Levodopa. Dtsch Med Wochenschr 109:1279–1283PubMedCrossRefGoogle Scholar
  25. Flückiger E, Briner U, Enz A, Markstein R, Vigouret M (1983) Dopaminergic ergot compounds: an overview. In: Calne D et al. (eds) Lisuride and other dopamine agonists. De Gruyter, Berlin New York, pp 59–88Google Scholar
  26. Friedman J H, Lannon MC (1989) Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology 39: 1219–1221PubMedCrossRefGoogle Scholar
  27. Frieling B (1989) Klinische PrÜfung der oralen Lisurid-Therapie bei Morbus Parkinson. In: Fischer PA, Frieling B (Hrsg) Morbus Parkinson — neue MÖglichkeiten mit Lisurid. De Gruyter, Berlin New York, S 59–88Google Scholar
  28. Fuxe K, Calne D (eds) (1979) Dopaminergic ergot derivates and motor function. Pergamon Press, Oxford New York Toronto Sydney Paris FrankfurtGoogle Scholar
  29. Garcia CA, Tweedy JR, Blass JP, Mc Dowell FH (1982) Lecithin and Parkinson dementia. In: Corkin S et al. (eds) Alzheimer’s disease: a report of progress in research. Raven Press, New York, pp 443–443449 (Aging, vol 19)Google Scholar
  30. Gianutsos G, Chute S, Dunn JP (1985) Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol 110: 357–361PubMedCrossRefGoogle Scholar
  31. Giménez-Roldan S, Tolosa E, Burguera JA, Chacón J, Liaño H, Forcadell F (1997) Early combination of bromocriptine and levodopa in Parkinson’s disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 20: 67–76PubMedCrossRefGoogle Scholar
  32. Godwin-Austen RB, Frears CC, Bergmann S, Parkes JO, Knill-Jones RP (1970) Combined treatment of parkinsonism with L-Dopa and amantadine. Lancet ii: 383–385CrossRefGoogle Scholar
  33. Gopinathan G, Horowski R, Suchy I (1985) Lisu-ride pharmacology of Parkinson’s disease. Springer, Berlin Heidelberg New York Tokyo, pp 471–514Google Scholar
  34. Greulich W, Fenger E, Sackmann A, Gehlen W (1995) Langzeitwirkung der Amantadin-Therapie. In: Fischer PA (Hrsg) Parkinson-Krankheit. Bedeutung nichtdopaminerger FunktionsstÖrungen. Editiones Roche, Basel Grenzach/Wyhlen, S 315–321Google Scholar
  35. Hefner R, Fischer PA (1988) Interaktionen von Hochdruck-Therapeutika mit Parkinson-Mitteln. In: Fischer PA (Hrsg) Modifizierende Faktoren bei der Parkinson-Therapie. Editiones Roche, Basel, S 209–219Google Scholar
  36. Hefner R, Fischer PA (1989) Zunahme der Parkinson-Symptomatik unter Kalzium-Antagonisten. Nervenarzt 60: 187–188PubMedGoogle Scholar
  37. Hefner R, Baas H, Fischer PA (1988) Incompatibility of flunarizine in Parkinson’s disease. In: Bartko D et al. (eds) New trends in clinical neuropharmacology. Libbey, London Paris, pp 314–316Google Scholar
  38. Horowski R, Obeso JA (1995) Lisuride. A direct dopamine agonist in the symptomatic treatment of Parkinson’s disease. In: Koller WC, Paulson G (ed) Therapy of Parkinson’s disease. Marcel Dekker, New York Basel Hongkong, pp 219–248Google Scholar
  39. Horrocks PM, Vicary DJ, Rees JE, Parkes JD, Marsden CD (1973) Anticholinergic withdrawal and benzhexol treatment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 36: 936–941PubMedCrossRefGoogle Scholar
  40. Hughes RC, Polgar JG, Weightman D, Walton JN (1971) Levodopa in parkinsonism: the effects of withdrawal of anticholinergic drugs. Br Med J 2: 487–941PubMedCrossRefGoogle Scholar
  41. Hunter KR, Stern GM, Laurence DR, Armitage P (1970) Amantadine in parkinsonism. Lancet i: 1127–1129CrossRefGoogle Scholar
  42. Jorgensen PB, Bergin JD, Haas L, Cunningham JA, Morah DD, Pollock U (1971) Controlled trial of amantadine hydrochloride in Parkinson’s disease. NZ Med J 73: 263–269Google Scholar
  43. Kaufmann H, Elizan T, Yahr MD, Moros D, Van Woert M (1989) Deprenyl monotherapy in patients with early Parkinson’s disease: a clinical and biochemical study. Neurology 39[Suppl 1]: 229 (Abstract)Google Scholar
  44. Klawans H L, Goetz C H G, Tanner C M, Glantz R (1985) Studies with bromocriptine, In: Fahn S et al. (eds) Approaches to the use of bromocriptine in Parkinson’s disease. Raven Health Care Communications, New York, pp 37–45Google Scholar
  45. Kornhuber J, Bornemann J, Retz W, Hübers M, Riederer P (1989) Memantine displaces [3H] Mk-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589–590PubMedCrossRefGoogle Scholar
  46. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK 801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206: 297–300PubMedCrossRefGoogle Scholar
  47. Lees AJ, Stern GM (1981) Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 44: 1020–1023PubMedCrossRefGoogle Scholar
  48. Lees AJ on behalf of the Parkinson’s Disease Research Group of the United Kingdom (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson’s disease. BMJ 311: l602–602l607CrossRefGoogle Scholar
  49. Lieberman AN, Goldstein M (1985) Update on bromocriptine in Parkinson’s disease. In: Calne DB (ed) Drugs for the treatment of Parkinson’s disease. Springer, Berlin Heidelberg New York Tokyo, pp 443–458Google Scholar
  50. Lücking CH, Deuschl G, Strahl K, Schenk E (1986) Tremor im FrÜh-und Spätstadium der Parkinson-Krankheit. Editiones Roche, Basel, S 99–113Google Scholar
  51. Madersbacher H, Stöhrer M, Richter R, Burgdorfer H, Machen HJ, Mürtz G (1995) Trospium chloride versus oxybutynin: a randomized double blind, multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol 75: 452–456PubMedCrossRefGoogle Scholar
  52. Maier-Hoehn MM, Elton RL (1985) Low dosages of bromocriptine added to levodopa in Parkinson’s disease. Neurology 35: 199–206CrossRefGoogle Scholar
  53. Markham C H, Diamond SG (1985) Pergolide in the treatment of Parkinson’s disease. In: Calne DB (ed) Drugs for the treatment of Parkinson’s disease. Springer, Berlin Heidelberg New York Tokyo, pp 459–470Google Scholar
  54. Martin WK, Loewenson RP, Resch JA, Baker AP (1974) A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson’s disease. Neurology 35: 199–206Google Scholar
  55. Olanow CH, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J (1995) The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 38: 771–777PubMedCrossRefGoogle Scholar
  56. Ott BR, Lannon MC (1992) Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol 15: 322–325PubMedCrossRefGoogle Scholar
  57. Parkes JD (1989) Clinical pharmacology of amantadines and derivates. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Springer, Wien New York, pp 335–341CrossRefGoogle Scholar
  58. Poewe W, Gerstenbrand F, Ransmayr G (1987) Experience with selegiline in the treatment of Parkinson’s disease. J Neural Transm [Suppl] 25: 131–135Google Scholar
  59. Przuntek H (1994) Clinical aspects of neuroprotection in Parkinson’s disease. J Neural Transm 43 [Suppl]: 163–169Google Scholar
  60. Przuntek H, Welzel D, Gerlach M, Blümner E, Danielczyk W, Kaiser HJ, Kraus PH, Letzel H, Riederer P, überla K (1996) Early institution of bromocriptine in Parkinson’s disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm 103: 699–715PubMedCrossRefGoogle Scholar
  61. Rabey JM, Oberman Z, Scharf M, Isakov A, Bar M, Graff E (1989) The influence of levodopa on the pharmacokinetics of bromocriptine in Parkinson’s disease. Clin Neuropharmacol 12: 440–447PubMedCrossRefGoogle Scholar
  62. Rabey JM, Schwartz M, Graff E, Harsat A, Vered Y (1990) The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson’s disease. Clin Neuropharmacol 14: 514–522CrossRefGoogle Scholar
  63. Rascol A, Guirand E, Montrastuc JL, David J, Clanet MJ (1979) Long-term treatment of Parkinson’s disease with bromocriptine. J Neurol Neurosurg Psychiatry 42: 143–150PubMedCrossRefGoogle Scholar
  64. Ring HA, Trimble MR (1991) Affective disturbance in Parkinson’s disease. Int J Geriatr Psychiatry 6: 385–393CrossRefGoogle Scholar
  65. Rinne UK (1987a) Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a 5-year follow-up. Neurology 37: 826–826PubMedCrossRefGoogle Scholar
  66. Rinne UK (1987b) R-(-)-Deprenyl as an adjuvant to levodopa in the treatment of Parkinson’s disease. J Neural Transm [Suppl] 25: 149–155Google Scholar
  67. Rinne UK (1989) Die Bedeutung einer frÜhzeitigen Kombination von Lisurid und L-Dopa in der Behandlung der Parkinson-Krankheit. In: Fischer PA, Frieling B (Hrsg) Morbus Parkinson — neue MÖglichkeiten mit Lisurid. De Gruyter, Berlin New York, S 99–110Google Scholar
  68. Rinne UK (1991) Early use of dopaminerge agonists in the treatment pf Parkinson’s disease. In: Rinne UK, Nagatsu T, Horowski R (eds) International Workshop Parkinson’s Disease, Berlin. Medicom Europe BV, Bussum, pp 326–336Google Scholar
  69. Sage JI, Duvoisin RC (1995) Pergolide. In: Koller WC, Paulson G (eds) Therapy of Parkinson’s disease. Marcel Dekker, New York Basel Hongkong, pp 249–259Google Scholar
  70. Sandyk R (1985) Parkinsonism induced by Captopril. Clin Neuropharmacol 8: 197–198PubMedCrossRefGoogle Scholar
  71. Schifter R (1985) Neurologie des vegetativen Systems. Springer, Berlin Heidelberg New York TokyoCrossRefGoogle Scholar
  72. Schneider E (1995) Alpha-Dihydroergocryptin-Pharmakologie und klinische Effekte. In: Deuschl G (Hrsg) Morbus Parkinson. Alpha-Dihydroergocryptin — ein neuer Dopamin-Agonist. Thieme, Stuttgart New York, S 17–42Google Scholar
  73. Schneider E, Bressel M (1988) Behandlung von HarnblasenfunktionsstÖrungen beim Parkinson-Syndrom. In: Fischer PA (Hrsg) Modifizierende Faktoren bei der Parkinson-Therapie. Editiones Roche, Basel, S 221–232Google Scholar
  74. Schneider E, Fischer PA, Csiki C (1983) Stellenwert der Anticholinergika in der Behandlung des Parkinson-Syndroms. In: Gänshirt H (Hrsg) Pathophysiologie, Klinik und Therapie des Parkinsonismus. Editiones Roche, Basel, S 257–266Google Scholar
  75. Schneider E, Fischer PA, Jacobi P, Grotz A (1984a) Exogene Psychosen beim Parkinson-syndrom. Häufigkeit und Entstehungsbedingungen. Fortschr Neurol Psychiatr 52: 207–214PubMedCrossRefGoogle Scholar
  76. Schneider E, Ziegler B, Jacobi P (1984b) SchlafstÖrungen beim Parkinson-Syndrom. In: Fischer PA (Hrsg) VegetativstÖrungen beim Parkinson-Syndrom. Editiones Roche, Basel, S 163–183Google Scholar
  77. Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozopine and fluperlapine. Eur Arch Psychiatr Neurol Sci 235: 60–64CrossRefGoogle Scholar
  78. Shannon KM, Goetz CG, Garroll VS, Tanner CM, Klawans HL (1987) Amantadine and motor fluctuations in chronic Parkinson’s disease. Clin Neuropharmacol 6: 522–526CrossRefGoogle Scholar
  79. Shimoda K, Hikasa C, Nishikawa S, Takahashi K (1987) A case report of Captopril induced parkinsonism. Clin Neurol 27: 366–368Google Scholar
  80. Tetrud JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245: 519–522PubMedCrossRefGoogle Scholar
  81. Teychenne P, Bergstrud D, Racy A, Elton RL, Vern B (1982) Bromocriptine: low dose therapy in Parkinson’s disease. Neurology 32: 577–583PubMedCrossRefGoogle Scholar
  82. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 321: 1364–1371CrossRefGoogle Scholar
  83. The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183CrossRefGoogle Scholar
  84. The Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol 39: 37–45CrossRefGoogle Scholar
  85. Timberlake WH, Vance MA (1978) Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa. Ann Neurol 3: 119–128PubMedCrossRefGoogle Scholar
  86. van der Drift JHA (1977) Long-term clinical experience with levodopa and anticholinergics: therapeutic considerations. In: Lakke JPW et al. (eds) Parkinson’s disease. Concept and prospects. Excerpta Medica, Amsterdam Oxford, pp 111–116Google Scholar
  87. Verhagen Metman L, del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN (1998) Blockade of glutaminergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Amino Acids 14: 75–82PubMedCrossRefGoogle Scholar
  88. Völler GW (1970) Die Behandlung des Parkinson-Syndroms mit Amantadin. Dtsch Med Wochenschr 95: 934–937PubMedCrossRefGoogle Scholar
  89. Walker JE, Albers JW, Tourtelotte WW, Henderson WG, Potvin AR, Smith A (1972) A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson’s disease. J Chron Dis 25: 149–182PubMedCrossRefGoogle Scholar
  90. Webster DD, Sawyer GT (1984) The combined use of amantadine HCl and levodopa/carbidopa in Parkinson’s disease. Curr Ther Res Clin Exp 35: 1010–1013Google Scholar
  91. Weiner WJ, Factor SA, Sanchez-Ramos JR, Singer C, Sheldon RN, Cornelius L, Ingenito A (1993) Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson’s disease. Neurology 43: 21–27PubMedCrossRefGoogle Scholar
  92. Wesemann W (1984) Aspekte zum Wirkungsmechanismus von Amantadinen. In: Danielczyk W, Wesemann W (Hrsg) Amantadin-Workshop, Edition Materia Medica. Sociomedico, Gräfelfing, S 15–23Google Scholar
  93. Whyte RR, Hunter KR, Laurence DR, Stern GM, Armitage P (1971) Levodopa and orphen-adrine hydrochloride in parkinsonism. Eur J Clin Pharmacol 4: 18–21PubMedCrossRefGoogle Scholar
  94. Wilson JA, Farquhar DL, Primrose WR, Smith RG (1987) Long term amantadine treatment. The danger of withdrawal. Scot Med J 32: 135PubMedGoogle Scholar
  95. Yahr MD (1971) Results of long-term administration of L-Dopa. In: de Ajuriaguerra J, Gauthier G (eds) Monoamines noyoux gris centraux et syndrome de Parkinson. Georg, Geneve, pp 403–410Google Scholar
  96. Zeldovicz LR, Huberman J (1973) Long-term therapy of Parkinson’s disease with amantadine, alone and combined with levodopa. Can Med Assoc J 109: 588–593Google Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • E. Schneider

There are no affiliations available

Personalised recommendations